Coronavirus Latest News

AstraZeneca’s new Covid treatment: what is it and how does it work?

Evusheld could offer higher protection against variants and help vulnerable people ward off virus

Australia’s drugs regulator, the Therapeutic Goods Administration (TGA), has granted “provisional determination” to pharmaceutical company AstraZeneca for a long-acting antibody cocktail which has shown promise in preventing Covid-19 in adults.

Provisional determination is an early step in the drugs approval process and means AstraZeneca can now submit further data to the TGA from human trials about how the treatment works and its safety. Once the TGA has scrutinised the data, and if it is satisfied with it, it may grant Evusheld “provisional approval” for use in Australia in limited circumstances. Further data must be collected and given to the TGA even if this occurs.

Sign up to receive an email with the top stories from Guardian Australia every morning

Continue reading…

Read the original article at The Guardian

Related Articles

Back to top button
Close